ROCHE HOLDING LTD S/ADR - RHHBY STOCK NEWS

Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.

Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.

10/13/2023 09:30 AM

News

Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis

Rhea-AI Summary

Roche announces positive results from Phase II FENopta study for fenebrutinib in relapsing multiple sclerosis

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.93%

Tags

10/12/2023 01:00 AM

News

New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided

Rhea-AI Summary

Roche announces new data for OCREVUS in multiple sclerosis at ECTRIMS-ACTRIMS Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.08%

Tags

10/11/2023 02:00 AM

News

Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions

Rhea-AI Summary

Roche announces positive late-breaking data on OCREVUS subcutaneous injection for multiple sclerosis treatment

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.63%

Tags

10/11/2023 02:00 AM

News

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

Rhea-AI Summary

Genentech announces positive results from Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic/Latinx people with relapsing MS

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.63%

Tags

10/10/2023 01:00 AM

News

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Rhea-AI Summary

Roche announces positive long-term results for Vabysmo in retinal vein occlusion

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.87%

Tags

10/10/2023 01:00 AM

News

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Rhea-AI Summary

Genentech announces positive long-term results for Vabysmo in macular edema due to retinal vein occlusion

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.87%

Tags

10/04/2023 01:00 AM

News

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment

Rhea-AI Summary

Roche presents positive results from RAINBOWFISH study on Evrysdi treatment for babies with pre-symptomatic SMA, meeting primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of treatment. All babies were able to swallow and feed orally. Evrysdi is the only non-invasive SMA therapy approved in over 100 countries with more than 11,000 patients treated globally.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.15%

Tags

10/04/2023 01:00 AM

News

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

Rhea-AI Summary

Positive results from the RAINBOWFISH study show that 80% of babies treated with Evrysdi were able to sit without support for at least 5 seconds after 1 year of treatment. Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globally. The study also showed that all babies were able to swallow and feed orally, and none required permanent ventilation. Cognitive skills typical of normal child development were observed after 1 year of treatment. Adverse events were not considered treatment-related and there were no deaths or withdrawals. Early treatment for SMA before symptoms appear is valuable in preserving motor neurons.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.15%

Tags

10/02/2023 01:00 AM

News

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

Rhea-AI Summary

Roche will present new data for OCREVUS and fenebrutinib for multiple sclerosis (MS) and ENSPRYNG for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. OCREVUS shows significant benefit in slowing long-term disability progression and consistent long-term safety profile in MS. Real-world and clinical data demonstrate impact for underrepresented populations. Safety outcomes from more than 6,000 patients across 12 OCREVUS trials support its favorable safety profile over 10 years. ENSPRYNG shows promising results in NMOSD with lower infection rates compared to other treatments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.56%

Tags

10/02/2023 01:00 AM

News

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

Rhea-AI Summary

Genentech will present new data for Ocrevus and fenebrutinib for multiple sclerosis (MS) and Enspryng for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. Ocrevus shows significant benefit in slowing long-term disability progression and has a consistent safety profile. Real-world and clinical data demonstrate the impact of Ocrevus in underrepresented populations. Enspryng shows long-term safety and efficacy in NMOSD. Fenebrutinib demonstrates brain penetration and reduction of new lesion activity in MS.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.56%

Tags

FAQ

What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?

The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $34.96 as of December 24, 2024.

What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?

The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 235.1B.

What is Roche Holdings Ltd. S/ADR (RHHBY) known for?

Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.

What is the significance of Columvi® (glofitamab) in Roche's portfolio?

Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does Roche contribute to personalized healthcare?

Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.

What recent innovation has Roche introduced in digital pathology?

Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.

What is Roche's approach to advancing haematology treatments?

Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.